This report presents the results of the seventh round of the external quality assessment (EQA-7) scheme for Listeria monocytogenes (L. monocytogenes) typing organised for national public health reference laboratories (NPHRLs) providing data to the Food- and Waterborne Diseases and Zoonoses Network (FWD-Net) managed by ECDC.
This report presents the objectives, methods, results, and conclusions of a collaborative study called the 'European Listeria Typing Exercise’ (ELiTE), as well as recommendations for further studies.
A collaborative study between ECDC, the European Food Safety Authority (EFSA) and the European Union Reference Laboratory (EURL) for Listeria monocytogenes* found a relatively high degree of dissemination of certain listeriosis bacteria in the food chain and in the human population across the European Union (EU).
The number of reported human cases of illness caused by Campylobacter and Salmonella bacteria across Europe appears to have stabilised over the past five years, according to the latest report on zoonotic diseases by EFSA and ECDC.
This report of the EFSA and ECDC presents the results of zoonoses monitoring activities carried out in 2019 in 36 European countries (28 Member States (MS) and eight non-MS).
For 2019, EU/EEA countries reported five human Lyssavirus infections. Four human cases of travel-related rabies were reported by Italy, Latvia, Spain and Norway with exposure in Tanzania, India, Morocco and the Philippines, respectively. One locally-acquired fatal case of European bat lyssavirus (EBLV-1) infection was reported by France.
This report provides an analysis of the external quality assessment (EQA) for the antimicrobial susceptibility testing (AST) performance of laboratories participating in the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2019. A total of 952 laboratories (1–95 per country) from 30 EU/EEA countries participated in the EQA exercise.
Rabies is a deadly disease and endemic in over 100 countries. It causes around 59,000 human deaths annually, the vast majority in Asia and Africa. There are safe and effective human vaccines for pre- and post-exposure prophylaxis. With a prompt and proper post-exposure prophylaxis (PEP), exposed people have a survival rate close to 100%.